Trial Profile
A retrospective study assessing safety and efficacy of Atezolizumab and subsequent therapies in patients with metastatic urothelial carcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Apr 2018
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary)
- Indications Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- 06 Apr 2018 Results assessing safety and efficacy of Atezolizumab and subsequent therapies in patients with metastatic urothelial carcinoma, were published in the Targeted Oncology.
- 20 Mar 2018 New trial record
- 10 Feb 2018 Results presented at the 2018 Genitourinary Cancers Symposium